Vignato, Julie A.
Gumusoglu, S. Banu
Davis, Heather A.
Scroggins, Sabrina M.
Hamilton, Wendy S.
Brandt, Debra S.
Pierce, Gary L.
Knosp, Boyd A.
Santillan, Donna A.
Santillan, Mark K. http://orcid.org/0000-0002-3991-8017
Funding for this research was provided by:
National Institute of Nursing Research (T32NR11147)
National Institute of Child Health and Human Development (R01HD089940, P50HD103556)
National Institute of Mental Health (T32MH01911328)
American Heart Association (18SCG34350001, 15 SFRN 23730000)
Article History
Received: 19 May 2022
Accepted: 11 August 2022
First Online: 19 August 2022
Declarations
:
: This study was IRB approved (IRB # 201,710,819 and MFTB IRB # 200,910,784) at the University of Iowa. Given the use of coded clinical data and biosamples provided by the MFTB, the IRB determined that the study is not considered human subjects research (IRB # 201,710,819).
: Informed consent was obtained from all individual participants included in the study.
: Not applicable.
: DAS and MKS hold patents related to the prediction and treatment of preeclampsia: US 293 #9,937,182 (April 10, 2018), EU #2,954,324, and PCT/US2018/027152. There are no other conflicts.
: This retrospective study involving human participants was performed in accordance with the ethical standards of the institutional research board and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of the University of Iowa approved this study.